Nalaganje...
Dual targeting of HER2-positive breast cancer with trastuzumab emtansine and pertuzumab: understanding clinical trial results
Targeting of HER2-positive tumors with trastuzumab has shown to improve survival in early stage and advanced breast cancer. The addition of pertuzumab, another anti-HER2 antibody, to trastuzumab-containing regimens has demonstrated a modest increase in disease-free survival in the adjuvant setting....
Shranjeno v:
| izdano v: | Oncotarget |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Impact Journals LLC
2018
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6112749/ https://ncbi.nlm.nih.gov/pubmed/30159132 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.25739 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|